Department of Otolaryngology-Head and Neck Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Department of Hearing and Speech Science, Vanderbilt Bill Wilkerson Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Laryngoscope. 2023 Sep;133(9):2362-2370. doi: 10.1002/lary.30452. Epub 2022 Oct 18.
To report our experience for adults undergoing cochlear implantation (CI) for single-sided deafness (SSD).
This is a retrospective case series for adults with SSD who underwent CI between January 2013 and May 2021 at our institution. CNC and AzBio speech recognition scores, Tinnitus Handicap Inventory (THI), Speech, Spatial, and Qualities of Hearing Scale (SSQ12), datalogging, and the Cochlear Implant Quality of Life (CIQOL)-10 Global measure were utilized.
Sixty-six adults underwent CI for SSD (median 51.3 years, range 20.0-74.3 years), and 57 (86.4%) remained device users at last follow-up. Compared to pre-operative performance, device users demonstrated significant improvement in speech recognition scores and achieved peak performance at six months post-activation for CNC (8.0% increased to 45.6%, p < 0.0001) and AzBio in quiet (12.2% increased to 59.5%, p < 0.0001). THI was decreased at 6 months post-implantation (58.1-14.6, p < 0.0001), with 77% of patients reporting improved or resolved tinnitus. Patients demonstrated improved SSQ12 scores as well as the disease-specific CIQOL-10 Global questionnaire. Duration of deafness was not associated with significant differences in speech recognition performance. Average daily wear time was positively associated with CNC and AzBio scores as well as post-operative CIQOL-10 scores.
Herein we present the largest cohort of adult CI recipients with SSD with data on speech recognition scores, tinnitus measures, and SSQ12. Novel insights regarding the correlation of datalogging, duration of deafness, and CI-specific quality of life (CIQOL-10) metrics are discussed. Data continue to support CI as an efficacious treatment option for SSD.
4 Laryngoscope, 133:2362-2370, 2023.
报告我们在单侧聋(SSD)成人中进行人工耳蜗植入(CI)的经验。
这是一项回顾性病例系列研究,纳入了 2013 年 1 月至 2021 年 5 月期间在我院接受 SSD 成人 CI 的患者。使用 CNC 和 AzBio 言语识别评分、耳鸣残疾量表(THI)、言语、空间和听觉质量量表(SSQ12)、数据记录和人工耳蜗生活质量量表(CIQOL-10)进行评估。
66 例成人接受了 SSD 的 CI(中位数 51.3 岁,范围 20.0-74.3 岁),57 例(86.4%)在最后一次随访时仍为设备使用者。与术前表现相比,设备使用者的言语识别评分显著提高,并在激活后 6 个月时达到 CNC(从 8.0%增加到 45.6%,p<0.0001)和安静环境下的 AzBio(从 12.2%增加到 59.5%,p<0.0001)的峰值表现。植入后 6 个月时 THI 降低(58.1-14.6,p<0.0001),77%的患者报告耳鸣得到改善或缓解。患者的 SSQ12 评分以及特定于疾病的 CIQOL-10 全球问卷评分均得到改善。耳聋持续时间与言语识别表现无显著差异。平均每日佩戴时间与 CNC 和 AzBio 评分以及术后 CIQOL-10 评分呈正相关。
在此,我们报告了最大的单侧聋成人 CI 接受者队列,提供了言语识别评分、耳鸣评估和 SSQ12 的数据。讨论了与数据记录、耳聋持续时间和特定于 CI 的生活质量(CIQOL-10)指标相关的新见解。数据继续支持 CI 作为 SSD 的有效治疗选择。
4 Laryngoscope, 133:2362-2370, 2023.